EM1810E "Nonalcoholic Fatty Liver Disease Turns 38-What Have We Learned?" (IM GR-100518)
To discuss and explain the underlying mechanisms responsible for the development of nonalcoholic fatty liver disease as well as the mechanism of action for new drugs under development for the treatment of nonalcoholic fatty liver disease.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Understand the underlying changes in fatty acid metabolism that result in fat accumulation in liver.
- Understand the genetic contributions to NAFLD.
- Understand the risk factors associated with the development of NAFLD.
Jay Horton, M.D.
Professor of Internal Medicine and Molecular Genetics
Division of Digestive & Liver Diseases
Director, Center for Human Nutrition
Scott Grundy Director’s Chair
The Robert C. and Veronica Atkins Chair in Obesity & Diabetes Research Distinguished Chair in Human Nutrition
Dr. Jay D. Horton is the Director of the Center for Human Nutrition and Professor of Internal Medicine and Molecular Genetics. He obtained his B.S. and M.D. degrees from the University of Iowa and completed his Internal Medicine residency, gastroenterology fellowship, and Howard Hughes post-doctoral fellowship at UT Southwestern. Dr. Horton’s research interests are in determining how regulators of fat metabolism contribute to the development of fatty liver and delineating the function of PCSK9, a protein secreted into the blood that regulates LDL receptors in the liver.
- 1.00 AMA